[1][2] NR (nicotinamide riboside): In a randomized, double-blind, placebo-controlled trial in adults ages 55 to 79, 500 mg twice daily for six weeks raised NAD+ levels in peripheral blood mononuclear cells by about 60%
We administer BPC-157 injections with precision, ensuring targeted delivery for optimal results
Now 52, Asprey splits his time between Austin and Victoria, British Columbia
A nasal spray must penetrate nasal mucosa, possibly deal with mucociliary clearance, and may have somewhat reduced bioavailability
But BPC-157 brings it back down
ICH Q2(R2) emphasizes that representative analytical data should identify relevant components where appropriate [13]